-transparent.png){kind=logo}
We examined the tumor necrosis factor (TNF alpha) bioactivity in patients with chronic glomerulonephritis (CGN) treated with methylprednisolone (MP) pulse therapy (1 course of 1 g/day x 3 days). TNF alpha bioactivity in CGN, including 5 cases of membranoproliferative glomerulonephritis (MPGN), 8 lupus nephritis (LN) and 6 purpura nephritis, was determined by ELISA with TNF alpha monoclonal antibody. TNF alpha values in the serum, urine and cultured lymphocyte supernatant (CLS) of patients was significantly higher than in control. (serum: 131.6 +/- 20.2 vs 70.4 +/- 13.8, urine: 26.2 +/- 8.2 vs 11.2 +/- 2.0, P < 0.05, CLS: 97.4 +/- 9.8 vs 59.5 +/- 10.1, P < 0.05, pretreatment vs control), but it was markedly reduced after treated with MP therapy. (serum: 60.2 +/- 11.2 vs 131.6 +/- 20.2, P < 0.05, urine: 10.2 +/- 1.6 vs 26.2 +/- 8.2, P < 0.05, CLS: 54.1 +/- 11.2 vs 97.4 +/- 9.8, P < 0.05, posttreatment vs pretreatment). These results indicated that TNF alpha levels in serum, urine and supernatant of lymphocyte were markedly higher in chronic nephritis, the MP pulse therapy possessed a striking effect on inhibiting the production of TNF alpha in peripheral lymphocytes.
L Q Bai, and
X M Chen, and
J Mao
September 1982,
Nihon Jinzo Gakkai shi,
L Q Bai, and
X M Chen, and
J Mao
January 1976,
Lancet (London, England),
L Q Bai, and
X M Chen, and
J Mao
July 1982,
The Journal of pediatrics,
L Q Bai, and
X M Chen, and
J Mao
January 1996,
Srpski arhiv za celokupno lekarstvo,
L Q Bai, and
X M Chen, and
J Mao
January 1984,
Clinical and experimental rheumatology,
L Q Bai, and
X M Chen, and
J Mao
October 2001,
Pediatric nephrology (Berlin, Germany),
L Q Bai, and
X M Chen, and
J Mao
March 1989,
Southern medical journal,
L Q Bai, and
X M Chen, and
J Mao
February 1980,
Journal of pharmacobio-dynamics,
L Q Bai, and
X M Chen, and
J Mao
January 1987,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
L Q Bai, and
X M Chen, and
J Mao
January 1983,
Terapevticheskii arkhiv,
